← Back to Clinical Trials
Recruiting NCT05698966

NCT05698966 Low Dose Antenatal Corticosteroids for Late Preterm Delivery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05698966
Status Recruiting
Phase
Sponsor Rambam Health Care Campus
Condition Respiratory Morbidity
Study Type INTERVENTIONAL
Enrollment 1,510 participants
Start Date 2022-01-01
Primary Completion 2027-01-01

Trial Parameters

Condition Respiratory Morbidity
Sponsor Rambam Health Care Campus
Study Type INTERVENTIONAL
Phase N/A
Enrollment 1,510
Sex ALL
Min Age 18 Years
Max Age 45 Years
Start Date 2022-01-01
Completion 2027-01-01
Interventions
we will use reduced dose of acceptable corticosteroids treatment for preterm birth

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a study proposal for a clinical trial to evaluate the effectiveness of a reduced dose of antenatal betamethasone (a steroid medication) in preventing respiratory problems in late preterm infants (born between 34 and 36 weeks of gestation). The study will be conducted in medical centers in Israel and will involve women who are at high risk for delivering a late preterm infant. The participants will be randomly assigned to receive either a full dose (12 mg) or a quarter dose (3 mg) of betamethasone, administered 24 hours apart. The main outcome measure of the study will be the incidence of respiratory problems or neonatal death within 72 hours of delivery in the two groups. The study is designed to determine if the reduced dose of betamethasone is non-inferior (i.e., not significantly worse) than the full dose in preventing respiratory problems in late preterm infants.

Eligibility Criteria

Inclusion Criteria:- - Singleton pregnancy at 34 weeks 0 days to 36 weeks 5 days of gestation at risk for / high probability of delivery in the late preterm period (34+0-36+5 weeks of gestation). Criteria for determination of late preterm delivery risk: 1. Preterm uterine contractions with intact membranes, and at least 3 cm dilation or 75% cervical effacement 2. Spontaneous rupture of the membranes 3. Expected preterm delivery for any other indication via induction or cesarean between 24 hours to 7 days after the planned randomization, as determined by the obstetric provider. \- Exclusion Criteria: They had already received a full course of betamethasone. * Expected delivery in less than 12 hours, irrespective of cause including: 1)ruptured membranes in the presence of more than 6 contractions per hour or cervical dilation of 3 centimeters or more unless oxytocin was withheld for at least 12 hours (although other induction agents were allowed), 2) chorioamnionitis, 3) cervical dilatio

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology